---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-003162"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:42:02.934734+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics reports FY2022 net loss $101.1M; STK-001 shows 55% median seizure reduction

## Summary
- Net loss for FY2022 was $101.1M ($2.60/share) vs $85.8M ($2.34/share) in 2021; revenue of $12.4M from license agreement.
- STK-001 interim analysis: 55% median reduction in convulsive seizure frequency in 6 patients after multiple 45mg doses.
- Cash, equivalents, and marketable securities $230.2M at Dec 31, 2022; plus $44.7M raised since, extending runway to end of 2025.
- Data from multiple 45mg doses expected mid-2023; 70mg dose data in H2 2023; Phase 3 program planned for 2024.
- R&D expenses rose to $77.8M (FY2022) from $54.2M (FY2021) driven by STK-001 and STK-002 development.

## SEC filing metadata
- accession: 0001564590-23-003162
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000156459023003162/0001564590-23-003162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000156459023003162/stok-8k_20230306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-003162
- JSON: https://secwatch.observer/filing/0001564590-23-003162.json
- Plain text: https://secwatch.observer/filing/0001564590-23-003162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.